SM
ALDX icon

Scoggin Management’s Aldeyra Therapeutics ALDX Stock Holding History

Scoggin Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$66.8K – 54
2023
Q3 		$66.8K Buy
+10,000
New +$74.2K 0.03% 61

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Scoggin Management's ALDX Position: Q4 2023 in Review

Scoggin Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 10,000 shares — an estimated $66.8K sold.

Scoggin Management first reported a position in ALDX in Q3 2023 and held it in 1 quarter. The position peaked at $66.8K in Q3 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

  • Scoggin Management reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Scoggin Management sold 10,000 Aldeyra Therapeutics shares in Q4 2023, an estimated $66.8K.
  • Scoggin Management first reported a position in Aldeyra Therapeutics in Q3 2023 and held it in 1 quarter.
  • Scoggin Management's Aldeyra Therapeutics position peaked at $66.8K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Scoggin Management's 13F filing for Q4 2023, filed 14 Feb 2024.